JHL Biotech Receives Cancer Biosimlar Clinical Trial Application Approval in China

11:16 EDT 15 Oct 2018 | Pharmaceutical Processing

News
JHL's China NMPA Phase III trial approval together with the UK MHRA trial approval mark the start of JHL's global Phase III clinical trial program.
Contributed Author: 
JHL Biotech
Topics: 
Drug Discovery and Development

More From BioPortfolio on "JHL Biotech Receives Cancer Biosimlar Clinical Trial Application Approval in China"